Cardiopulmonary Disease Diagnostics and Treatment Market: Disease Type (Cardiovascular and Respiratory Diseases), Type (Diagnosis-Electrocardiogram and Treatment -Medication), End-Users (Hospitals, Diagnostic Centers) --Global Forecast Till 2030

Cardiopulmonary Disease Diagnostics and Treatment Market Scenario

The Cardiopulmonary Disease Diagnostics and Treatment Market is anticipated to reach USD 3.32 Billion by 2030 at 6.80% CAGR during the forecast period 2022-2030. The cardiopulmonary disease is used to describe a wide range of series of disorders which affect the heart and the lungs. Cardiovascular disease is a universal term for conditions affecting the heart or blood vessels. It's usually related with a build-up of fatty deposits inside the arteries known as atherosclerosis. It can also be related with an injury to arteries in organs such as the brain, kidney, and heart. Respiratory disease is a medical term that includes extreme conditions affecting the organs and tissues which make gas exchange possible in higher organisms. Respiratory diseases range from mild to self-limiting, such as the common cold, to life-threatening entities like bacterial pneumonia, pulmonary embolism, and lung cancer.

Treatment options vary depending on the type of cardiopulmonary disease present and may include changes in diet or lifestyle, use of medications issued on prescription or surgery. The most common cardiopulmonary diseases are hypertension, stroke, and coronary heart disease. Untreated, cardiopulmonary diseases can be deadly. Cardiopulmonary diseases are the major cause of death globally.

The substantial growth in the frequency of health conditions related to the lungs and heart is the key factor to boosts the growth of this market. Also, the increase in aged population and the rising frequency in cardiovascular and respiratory diseases is also anticipated to drive the global market over the forecast period. Exposure to nicotine, tobacco products, and others increases the risk of obtaining cardiopulmonary diseases.

Increase in the rise of advanced technological equipment’s for diagnosing the disease will drive market rate exponentially. However, the huge cost of treatment and the regulatory nature of government on pharmaceutical companies will hamper the growth of the market.

Segmentation

The cardiopulmonary disease diagnostics and treatment market has been segmented on the basis of disease type, type, and end-user.

On the basis of disease type, the market has been classified as cardiovascular and respiratory diseases. The cardiovascular diseases are segmented into coronary artery disease, angina pectoris, myocardial infarction, dysrhythmia, hypertension, and others. The respiratory diseases are segmented into influenza, asthma, bronchitis, emphysema, cystic fibrosis, and others.

On the basis of type, the market has been classified as diagnosis and treatment. The diagnosis market is segmented into an electrocardiogram (ECG), Holter monitoring, echocardiogram, stress test, cardiac catheterization, cardiac computerized tomography (CT) scan, cardiac magnetic resonance imaging (MRI), single-photon emission computed tomography (SPECT), stress blood pressure monitors, pulse oximeters and spirometry. The treatment market is segmented into medications. The medications segment is further sub-segmented into angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBS), anticoagulants, antiplatelet agents and others.

On the basis of end users, the market has been classified as hospitals, clinics, diagnostic centers, specialty clinics and rehab centers, research institutes and others.

On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.

The European cardiopulmonary disease diagnostics and treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The cardiopulmonary disease diagnostics and treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The cardiopulmonary disease diagnostics and treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.

Regional Market Summary

Cardiopulmonary Disease Diagnostics and Treatment Market Share, by Region, 2017 (%)

Source: MRFR Analysis

In the cardiopulmonary disease diagnostics and treatment market, North America is anticipated to account for the largest market share due to the early adoption of advanced medical technologies, the rise in awareness, the rise in growth of the healthcare sector, and due to favorable compensation setting for many surgical procedures.

The European market is expected to hold the second largest market share. The market growth in this region can be attributed to rising frequency of cardiovascular disorders, increasing number of surgeries and increasing demand for advanced treatment procedures are boosting the European market.

The market share in Asia-Pacific is also projected to experience growth in the near future due to access to optimal treatment facilities and growing demand for advanced technology, better adoption rate, increase in disposable income, and rising medical tourism.

The market in the Middle East and Africa is expected to account for the smallest share of the cardiopulmonary disease diagnostics and treatment market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.

Key Players

Some of the key players in the cardiopulmonary disease diagnostics and treatment market are Cardinal Health, Cosmed Medical, GE Healthcare, Halma plc, Hill-Rom Holdings, Inc., Koninklijke Philips N.V., MGC Diagnostics Corporation, NIHON KOHDEN CORPORATION, Schiller AG, Masimo Corporation, and Vyaire Medical Inc.

Cardiopulmonary Disease Diagnostics and Treatment Market, by Disease Type

Cardiovascular diseases

• Coronary artery disease


• Angina pectoris


• Myocardial infarction


• Dysrhythmia


• Hypertension


• Others

Respiratory diseases

• Influenza


• Asthma


• Bronchitis


• Emphysema


• Cystic fibrosis


• Others

Cardiopulmonary Disease Diagnostics and Treatment Market, by Type

Diagnostics

• Electrocardiogram (ECG)


• Holter monitoring


• Echocardiogram


• Stress test


• Cardiac catheterization


• Cardiac computerized tomography (CT) scan


• Cardiac magnetic resonance imaging (MRI)


• Single-photon emission computed tomography (SPECT)


• Stress blood pressure monitors


• Pulse oximeters


• Spirometry

Treatment

• Medication


• Angiotensin-converting enzyme (ACE) inhibitors


• Angiotensin II receptor blockers (ARBS)


• Anticoagulants


• Antiplatelet agents


• Others

Cardiopulmonary Disease Diagnostics and Treatment Market, by End-User

• Hospitals


• Clinics


• Diagnostic centers


• Specialty Clinics and Rehab Centers


• Research Institutes


• Others

Cardiopulmonary Disease Diagnostics and Treatment Market, by Region

Americas

• North America


• US


• Canada


• South America

Europe

• Western Europe


• Germany


• France


• Italy


• Spain


• UK


• Rest of Western Europe


• Eastern Europe

Asia-Pacific

• Japan


• China


• India


• Australia


• South Korea


• Rest of Asia-Pacific

Middle East & Africa

• Middle East


• Africa

Intended Audience

• Governmental Agency


• Educational Organizations


• Medical Device Manufacturers


• Research Institutes and Academic Centers


• Market Research and Consulting